| 卓健伟,杨理坤,朱 洁,陈卫良,王玉海.阿托伐他汀对慢性硬膜下血肿患者术后MBI、CSS评分的影响[J].,2020,(18):3582-3586 |
| 阿托伐他汀对慢性硬膜下血肿患者术后MBI、CSS评分的影响 |
| Effect of Atorvastatin on the MBI and CSS Scores of Chronic Subdural Hematoma Patients after Operation |
| 投稿时间：2020-04-06 修订日期：2020-04-30 |
| DOI：10.13241/j.cnki.pmb.2020.18.041 |
| 中文关键词: 慢性硬膜下血肿 阿托伐他汀 炎症 改良barthel指数 中国卒中量表 |
| 英文关键词: Chronic subdural hematoma Atorvastatin Inflammation Coagulation function Modified Barthel index Chinese Stroke Scale |
| 基金项目:江苏省卫健委重点科研项目(K2019018) |
|
| 摘要点击次数: 550 |
| 全文下载次数: 391 |
| 中文摘要: |
| 摘要 目的：探讨阿托伐他汀对慢性硬膜下血肿(CSDH)患术后改良barthel指数(MBI)和中国卒中量表(CSS)评分的影响。方法：选择2014年2月至2019年2月我院接诊的126例CSDH术后患者进行研究，通过随机数表法将其分为观察组和对照组，每组各63例。两组患者均接受钻孔引流术，对照组术后给予常规处理，观察组联合阿托伐他汀口服治疗，均持续用药1个月。比较两组治疗前后血清神经元特异性烯醇化酶(NSE)、人S100B蛋白(S-100B、肿瘤坏死因子-α(TNF-α)、白介素-1(IL-1)、MBI、CSS评分的变化情况及不良反应的发生情况和复发情况。结果：观察组治疗后血清NSE、S-100B、CRP、TNF-α、IL-1水平均低于对照组(P＜0.05)，MBI评分高于对照组，CSS评分低于对照组(P＜0.05)；两组不良反应发生率比较差异无统计学意义(P＞0.05)，观察组复发率明显低于对照组(P＜0.05)。结论：阿托伐他汀能降低CSDH患者患术后炎症反应，提高MBI、CSS评分，降低复发率，且不增加不良反应。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effect of atorvastatin on the modified barthel index (MBI) and Chinese stroke scale (CSS) scores in patients with chronic subdural hematoma (CSDH). Methods: A total of 126 postoperative patients with CSDH treated in our hospital from February 2014 to February 2019 were selected for study. They were divided into observation group and control group by random number table method, with 63 cases in each group. The patients in both groups were treated by drilling and drainage. The patients in the control group were treated with routine treatment after operation. The observation group was treated with atorvastatin orally for one month. Before and after treatment, the serum neuron-specific enolase (NSE), human S100B protein (S-100B, tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), MBI, CSS scores were compared Changes and the occurrence and recurrence of adverse reactions. Results: After treatment, the levels of serum NSE, S-100B, CRP, TNF-α and IL-1 as well as CSS score in the observation group were lower than those in the control group (P<0.05), while the MBI score was higher than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). The recurrence rate in the observation group was significantly lower than that in the control group(P<0.05). Conclusion: Atorvastatin can relieve the postoperative inflammatory reaction, improve MBI and CSS scores, reduce the recurrence rate without increasing the adverse reactions. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
